Boston Scientific reports Q1 adjusted EPS 75c, consensus 67c

Reports Q1 revenue $4.66B, consensus $4.57B. “We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific (BSX). “We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term.”